JANX
Janux Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$20.24
+2.22%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.8x
Market Cap
$1.24B
MomentumView details →
1D Return
+2.22%
YTD Return
+44.82%
RSI (14)
73.9
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.8x
Market Cap
$1.24B
RSI (14)
73.9
MomentumView details →
1D Return
+2.22%
YTD Return
+44.82%
SummaryUpdated Jun 1, 2026
Janux Therapeutics, Inc. (NASDAQ:JANX) is a clinical-stage biopharmaceutical company founded in 2017 and headquartered in La Jolla, California. The company went public in June 2021 and focuses on developing innovative cancer immunotherapies using its proprietary platform technologies. Janux specializes in creating next-generation T-cell engager therapies designed to harness the body's immune system to fight cancer more effectively than traditional treatments.
Similar companies
Latest newsMore news →